Oculis to present key diabetic macular edema and optic neuritis study results at ARVO 2026 meeting

Oculis Holding AG announced it will present new findings on diabetic macular edema (DME) and optic neuritis treatments at the ARVO 2026 Annual Meeting. Highlights include results from the DME AWARE Delphi Study emphasizing the need for non-invasive therapies, and Phase 2 trial data for Privosegtor showing neuroprotective benefits in optic neuritis. The company is nearing topline results for its OCS-01 eye drops in DME, expected in June 2026, which could offer a non-invasive treatment alternative. Oculis is advancing multiple late-stage programs aimed at addressing significant unmet needs in ophthalmology and neuro-ophthalmology.